Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages.
The scaffold attachment region of the human interferon beta gene (IFN-SAR) inserted into a retroviral vector improved transgene expression in human primary CD4+ and CD8+ T cells, and in primary monocytemacrophages. In T cells, expression of the Maloney murine leukemia virus (Mo-MuLV)-based retroviral vectors was high in activated cells but low in resting cells. Addition of the IFN-SAR sequence enhanced vector expression 2- to 10-fold, and the effect was particularly pronounced in resting T cells. In CD33+CD14+CD4+ monocyte-macrophages derived from transduced hematopoietic stem/progenitor cells (HSPCs) in vitro, the IFN-SAR enhanced vector expression three- to sixfold. We have used the IFN-SAR-containing vectors to express the RevM10 gene, a trans-dominant mutant of the human immunodeficiency virus type 1 (HIV-1) rev gene. Compared with a standard retroviral vector, the IFN-SAR-containing vector was significantly (p < 0.01) more potent at inhibiting HIV-1 replication in infected CD4+ peripheral blood lymphocytes. In monocytes, however, addition of the IFN-SAR did not significantly improve antiviral efficacy. To understand better the reason for the strong effect of the SAR on antiviral efficacy in T cells we have studied the expression of HIV, Mo-MuLV, and Mo-MuLV + SAR vectors in resting and activated cells. While the expression of all three vectors was lower in resting compared with activated cells, the kinetics of the decrease in expression were fastest for the Mo-MuLV vector, followed by the HIV vector and then the Mo-MuLV + SAR vector. Thus, higher level expression of the Mo-MuLV + SAR vector relative to wild-type HIV at all stages of T cell activation is the most likely explanation for the strong antiviral efficacy. Overall, this study demonstrates the utility of the IFN-SAR sequence for achieving high-level retroviral vector expression in lymphoid and myeloid hematopoietic cells.
Auten
J
J
SyStemix, Inc., Palo Alto, CA 94304, USA.
Agarwal
M
M
Chen
J
J
Sutton
R
R
Plavec
I
I
D000818:Animals; D001665:Binding Sites; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000821:virology; D002478:Cells, Cultured; D015870:Gene Expression; D015694:Gene Products, rev / Q000235:genetics; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D015497:HIV-1 / Q000235:genetics / Q000502:physiology; D006801:Humans; D016899:Interferon-beta / Q000235:genetics*; D007700:Kinetics; D008264:Macrophages / Q000166:cytology / Q000821:virology; D051379:Mice; D008979:Moloney murine leukemia virus; D009000:Monocytes / Q000166:cytology / Q000821:virology; D012045:Regulatory Sequences, Nucleic Acid; D014162:Transfection; D019076:Transgenes; D054321:rev Gene Products, Human Immunodeficiency Virus
D015694:Gene Products, rev; D054321:rev Gene Products, Human Immunodeficiency Virus; D016899:Interferon-beta